The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2017 | Tackling urgent questions in EGFRm NSCLC
Nicolas Girard, MD, from the Claude Bernard University, Lyon, France, discusses the key challenges that we are facing in the management of thoracic cancers at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Dr Girard also describes the FLAURA (NCT02296125) study, which investigated erlotinib and gefitinib in patients with EGFR mutated non-small cell lung cancer. This trial had promising results, however, results determining overall survival are yet to be obtained.
